Icos Corporation

Kathleen S Keegan

Kate Loughney

Edward A Kesicki

Laurence Edward Burgess

Adam Wade Cook

John Joseph Gaudino

Scott D Cowen

Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.

Compounds useful for inhibiting Chk1

Polynucleotides encoding novel Atr-2 cell cycle checkpoint polypeptides are disclosed, along with expression constructs comprising the polynucleotides, host cells transformed with the expression constructs, methods to make the Atr-2 polypeptides using the host cells, Atr-2 polypeptides, and binding partners of the Atr-2 polypeptides.

ATR-2 cell cycle checkpoint

The present invention relates generally to a novel CREBa polypeptide isoform, polynucleotides encoding the polypeptide, expression constructs comprising the polynucleotides, host cell transformed or transfected with the polynucleotides, methods for producing the polypeptide, and methods to identify inhibitors of binding between the CREBa and other polypeptides or polynucleotides.

Creba isoform

CREBA isoform

Creba Isoform

Growing community of inventors

Mercer Island, WA, United States of America

Kathleen S Keegan